Recipharm AB today announced the appointment of Henrik Stenqvist as Recipharm’s new Executive Vice President and Chief Financial Officer, effective on April 24, 2017. He will be based at the company’s headquarters in Stockholm, Sweden and reports to Thomas Eldered, Chief Executive Officer of Recipharm.
Henrik Stenqvist brings 24 years’ finance and management experience to Recipharm. Prior to joining Recipharm he served as CFO of the Meda Group and held other leading finance positions in the pharmaceutical industry. He holds a degree in Finance and Business Administration from the University of Linköping, Sweden.
Thomas Eldered says “I am very pleased to welcome Henrik, his extensive experience and perspectives in finance, business and strategic development in the pharmaceutical industry make him a great fit for Recipharm as we continue on our strong growth path.”
Henrik Stenqvist says “I’m looking forward to contributing to the continued success of Recipharm in my new capacity as Chief Financial Officer of this leading company.”
Contact information
Thomas Eldered, CEO, telephone: +46 8 602 52 10
This information is information that Recipharm AB is obliged to make public pursuant to the EU Market Abuse Regulation.
The information was submitted for publication, through the agency of the contact persons set out above, on 11 April 2017, at 07:45 am CET.
About Recipharm
Recipharm is a leading Contract Development and Manufacturing Organisation (CDMO) in the pharmaceutical industry employing around 5 000 employees. Recipharm offers manufacturing services of pharmaceuticals in various dosage forms, production of clinical trial material and APIs, and pharmaceutical product development. Recipharm manufactures several hundred different products to customers ranging from big pharma to smaller research and development companies. Recipharm’s turnover is approximately SEK 5.3 billion and the company operates development and manufacturing facilities in France, Germany, India, Israel, Italy, Portugal, Spain, Sweden, the UK and the US and is headquartered in Stockholm, Sweden. The Recipharm B-share (RECI B) is listed on Nasdaq Stockholm.
For more information on Recipharm and our services, please visit www.recipharm.com
Recipharm AB (publ)
Corporate identity number 556498-8425
Address Box 603, SE-101 32 Stockholm, Sweden, Telephone +46 8 602 52 00
www.recipharm.com
